Repros Therapeutics Inc.
2408 Timberloch Place
Suite B-7
The Woodlands,
TX 77380
United States - Map
Phone: 281-719-3400
Fax: 281-719-3446
Website: http://www.reprosrx.com
Repros Therapeutics Inc., a development stage biopharmaceutical company, engages in the development of new drugs to treat hormonal and reproductive system disorders. Its product portfolio includes Androxal, an oral therapy, which is in Phase III used for the treatment of low testosterone due to secondary hypogonadism; Proellex that is in Phase II used for the treatment of symptoms associated with uterine fibroids and endometriosis; and VASOMAX that is used for the treatment of male erectile dysfunction. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. Key Statistics
| |
| Repros Therapeutics Inc.’s ISS Governance QuickScore as of May 1, 2013 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 6. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Joseph S. Podolski ,
66
Chief Exec. Officer, Pres and Director | 681.00K | 0.00 | Ms. Katherine A. Anderson CPA,
55
Chief Financial Officer, Chief Accounting Officer and Sec. | 284.00K | 0.00 | Dr. Jaye L. Thompson Ph.D.,
47
Sr. VP of Clinical & Regulatory and Director | 28.00K | N/A | Dr. Ronald Wiehle Ph.D.,
64
VP of R&D | 209.00K | 0.00 | Dr. Joachim F. Wernicke M.D., Ph.D.,
65
Chief Medical Officer | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.08(0.51%) 9:38AM EDT - Nasdaq Real Time Price